Long-term manifestations and modifiers of prevalence estimates of the post-COVID-19 syndrome: A systematic review and meta-analysis.

Daniel De-la-Rosa-Martinez\*<sup>1,2</sup>, Marco Antonio Delaye-Martínez\*<sup>2</sup>, Omar Yaxmehen Bello-Chavolla<sup>3</sup>, Alejandro Sicilia-Andrade<sup>2</sup>, Isaac David Juárez-Cruz<sup>2</sup>, Carlos A. Fermín-Martínez<sup>2</sup>, Alejandro Márquez-Salinas<sup>2</sup>, Enrique Cañedo-Guerra<sup>2</sup>, Luisa Fernández-Chirino<sup>4</sup>, Mónica Martínez-Gutiérrez<sup>2</sup>, Daniel Eduardo Sandoval-Colin<sup>2</sup>, Diana Vilar-Compte<sup>1</sup>.

\*De-la-Rosa-Martinez and Delaye-Martinez contributed equally to this manuscript.

- Department of Infectious Diseases, Instituto Nacional de Cancerologia, Mexico City, México.
- 2. Plan de Estudios Combinados en Medicina (PECEM), Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
- 3. Division of Research, Instituto Nacional de Geriatría, Mexico City, Mexico
- 4. Faculty of Chemistry, Universidad Nacional Autónoma de México, Mexico City, Mexico

#### Corresponding author:

Diana Vilar-Compte, MD, MSc. Departamento de Infectologia, Instituto Nacional de Cancerologia. Av. San Fernando 22, Col. Sección XVI, Mexico City 14080, Mexico. T. +52 555 628 0400 ext. 12120. E-mail: diana\_vilar@yahoo.com.mx

Abstract

Background: Post-acute COVID-19 syndrome (PACS) is a multi-system disease comprising

persistent symptomatology after the acute phase of infection. Long-term PACS effects

significantly impact patient outcomes, but their incidence remains uncharacterized due to

high heterogeneity between studies. Therefore, we aimed to summarize published data on

PACS, characterizing the clinical presentation, prevalence, and modifiers of prevalence

estimates.

Method: In this systematic review and meta-analysis, we research MEDLINE for original

studies published from January 1st, 2020, to January 31st, 2021, that reported proportions of

PACS manifestations. Studies were eligible for inclusion if they included patients aged ≥18

years with confirmed COVID-19 by RT-PCR or antigen testing and a minimum follow-up of

21 days. The prevalence of individual manifestations across studies was pooled using

random-effects meta-analysis. For evaluating determinants of heterogeneity, meta-

regression analysis was performed. This study was registered in PROSPERO

(CRD42019125025).

**Results**: After screening 1,235 studies, we included 29 reports for analysis. Twenty-seven

meta-analyses were performed, and 61 long-term manifestations were described. The

pooled prevalence of PACS was 56% (95%Cl 45-66%), with the most common

manifestations being diminished health status, fatigue, asthenia, dyspnea, myalgias,

hyposmia and dysgeusia. Most of the included studies presented high heterogeneity. After

conducting the meta-regression analysis, we identified that age, gender, number of

comorbidities, and reported symptoms significantly modify the prevalence estimation of

PACS long-term manifestations.

Conclusion: PACS is inconsistently reported between studies, and population

characteristics influence the prevalence estimates due to high heterogeneity. A systematized

2

approach for the study of PACS is needed to characterize its impact adequately.

Funding: none

Keywords; COVID-19; PACS; SARS-CoV-2; Long COVID-19; Long-term; Prevalence

INTRODUCTION

Post-acute COVID-19 syndrome (PACS), also known as Long Covid, is a multi-system

disease that occurs after the acute phase of COVID-19. Most patients with COVID-19

develop a mild acute illness lasting 15 to 20 days [1,2]; however, a variable proportion of

patients persist with symptoms beyond four weeks from symptom onset. According to the

World Health Organization, PACS "occurs in individuals with a history of probable or

confirmed SARS CoV-2 infection, usually three months from the onset of COVID-19 with

symptoms that last for at least two months and cannot be explained by an alternative

diagnosis" [3]. Some studies have reported a prevalence of 10-33% of patients who undergo

prolonged illness lasting from several weeks to months after acute COVID-19. Although

these manifestations vary widely, the most common symptoms described are fatigue,

headache, cough, breathlessness, joint pain, muscle and chest pain, weakness,

gastrointestinal upset, rashes, chills, and olfactory and gustatory dysfunction. In addition,

some neurocognitive impairments such as depression, anxiety, and post-traumatic stress

syndrome have been highly reported.

Despite this growing available information, there is still uncertainty regarding the number and

variety of the long-term effects attributable to PACS. Moreover, in agreement with previous

observations in infections caused by Chikungunya, Ebola, Severe Acute Respiratory

Syndrome Coronavirus (SARS-CoV-1), and Middle East respiratory syndrome (MERS) virus,

these long-term manifestations could last for years after the acute infection [4-7]. Clinical

characterization of PACS is still ongoing, and some risk factors have been preliminarily

identified. Patients who developed severe COVID-19 are more likely to present long-term

effects however, patients with an initial mild course are not free from developing new or

persistent symptoms. In addition, some reports have placed women, patients admitted to the

intensive care unit, and those with specific comorbidities as higher risk groups for developing

long-term effects.

Recent data reporting the long-term effects of COVID-19 is showing a new landscape in

SARS-CoV-2 infection. In addition, the proportion of patients with sequelae after COVID-19

who require specialized medical attention, rehabilitation programs, and absence from work is

increasing, having profound medical, social, and economic implications which urgently need

to be addressed by governments and other stakeholders. Here, we conducted a systematic

review and metanalysis to evaluate data on the persistence of symptoms after acute COVID-

19, characterizing the clinical presentation and modifiers of prevalence estimates in PACS.

**METHODS** 

Search criteria

A sensitive reference search was conducted using MEDLINE (via PubMed) to include

manuscripts from January 1st, 2020, to January 31st, 2021. A preliminary search was made

in PubMed, looking for relevant studies reporting the clinical status of patients recovered

from COVID-19 several weeks after the acute illness. We focused on keywords included in

each article to establish a general landscape of how "persistent symptoms" were described.

Keywords included in our search were: post-discharge symptoms; long-COVID; recovery;

post-COVID syndrome; sequels; long-term consequences; persistent symptoms; post-

COVID; SARS-CoV-2 and COVID-19. Post-acute COVID-19 syndrome (PACS) was not

included as a keyword, as it has recently been described. With the selected keywords, we

designed a search algorithm in PubMed that combined Boolean operators (AND/OR), search

4

filters for language (English and Spanish), and year of publication (2020-2021).

Screening and data extraction

Three authors (DDRM, MADM, IDJC) screened article titles and abstracts of the initial

database search to identify those appropriate for complete text review. Pairs reviewed the

full text of identified articles according to the following selection criteria:

Patients with confirmed COVID-19 by RT-PCR or rapid antigen test

2. Adult population (>18 years old)

3. Acute symptomatic illness during SARS-CoV-2 infection

4. A period of follow-up ≥three weeks (21 days)

5. Reported the proportion of the specific persistent manifestations

Articles with confirmed reinfection cases were excluded from the analysis. For each included

manuscript, data were extracted and summarized in a standardized database by reviewers.

Quality assessment

Joanna Briggs Institute critical appraisal tools were used to evaluate quality of the studies

and PRISMA check list was used for reporting the findings. A third reviewer solved any

disagreement if the initial reviewers reported discordant results. This review was

prospectively registered in the PROSPERO database (Project number CRD42021243541).

**Variables** 

We included demographic, clinical characteristics, and outcomes likely related to PACS in

patients with previous COVID-19. Clinical signs and symptoms related to PACS were

reported as proportions and described individually and classified according to the organ

systems involved. Due to the nature of the pandemic and its rapid evolution, long-term

manifestations associated with COVID-19 are not universally recognized or previously

defined. Recently, the term PACS has been used as a reference in the literature. For this

study and in agreement with the evidence of active viral infection and infectivity, PACS was

defined as the persistence of symptoms ≥21 days after SARS-CoV-2 infection diagnosis [8].

5

Statistical analysis

We calculated the pooled prevalence of symptoms for studies in which 1) the total number of patients with COVID-19 and the total number of those with persistent symptoms were reported by the authors and 2) at least two or more studies reported the specific long-term manifestation. We used a random-effects meta-analysis for calculating pooled prevalence estimates using the Hartung-Knapp-Sidik-Jonkman variance estimator, and the I² statistic test was calculated to quantify the heterogeneity of the studies [9]. I² values to establish the degree of heterogeneity were >75% for high; 50-75% for substantial; 25-50% for moderate and <25% for low heterogeneity. Forest plots were made to visualize the pooled prevalence of each long-term manifestation.

In order to diminish heterogeneity and improve meta-analytic pooling, we performed an outlier removing analysis as follows: We identified a study as an outlier if 1) its confidence interval did not overlap with the confidence interval of the pooled effect, 2) the upper bound of the 95%CI was lower than the lower bound of the pooled effect CI or 3) the lower bound of the 95% CI was higher than the upper bound of the pooled effect CI or 4)A covariance ratio (CovRatio) value <1 of each manuscript [10]. CovRatio was calculated by dividing the variance of the pooled effect without each manuscript by the variance of the initial pooled effect. As a secondary objective, we looked for modifiers of PACS prevalence estimates: patients' age, gender, comorbidities, and the number of symptoms reported in each article. For this purpose, we performed a meta-regression analysis, and coefficients and 95% confidence intervals were calculated for those symptoms reported at least by three authors [11]. Statistical analyses were performed using the meta package in R software version 4.1.1.

**RESULTS** 

**Demographics characteristics** 

Twenty-nine articles were included in the analysis after the systematic review and selection criteria of all screened studies [12–40]. Twenty-two (75.8%), 3 (10.3%), 3 (10.3%) and 1

(3.4%) manuscripts were from Europe, America, Asia, and Africa, respectively. All articles were published during the second semester of 2020. The screening and selection process is shown in *Figure 1*. The number of patients included in the individual studies ranged from 23 to 4694, with a female proportion between 27 to 75%. The age range of participants was 27 to 70 years, and the period of follow-up since the onset of acute COVID-19 symptoms was 21 to 162 days. We did not identify studies with overlapping samples. The authors reported a wide range of comorbidities. Diabetes, hypertension, and obesity were reported in 17 (59%), 17 (59%), and 10 (37%) articles, respectively. Concerning the number of comorbidities, 6 (21%) manuscripts reported four or fewer, and 14 (48%) reported more than five comorbidities. No information on comorbidities was available for 8 (28%) manuscripts. Demographic and clinical characteristic of included studies are shown in *Table 1* 

#### Pooled prevalence of long-term PACS manifestations

For the pooled prevalence of persistent symptoms, 27 meta-analyses were performed, and 61 long-term manifestations as part of the PACS spectrum were described (Table 2). The general PACS prevalence was 56% (95%CI 45-66%), which included any new or persistent symptom after three weeks from COVID-19 onset. Fatigue (49%) and asthenia (32%) were the most prevalent constitutional symptoms after acute COVID-19. For cognitive manifestations, attention disorders and memory loss were reported in 27% and 23% of patients, respectively, while anxiety and post-traumatic stress disorders were reported in around 30%. The long-term prevalence and system involvement of PACS manifestations are shown in Figure 2.

The most frequent long-term respiratory symptoms were dyspnea (35%), and sputum (20%), followed by cough (19%). Myocardial edema and diastolic dysfunction were present in 1 of 2 patients; nevertheless, this prevalence was reported only by one article. Gastrointestinal symptoms and rectal or urinary incontinence were reported in no more than 10% of patients. Ophthalmological sequelae occurred in <20% of cases. Around 1 in 4 patients had myalgias

and arthralgias as part of musculoskeletal manifestations. For cutaneous signs, loss of hair was the most frequent finding. Sixty percent of the included participants reported a diminished overall health perception, and sleep disorders were observed in one-third. In addition, the report by Kamal et al. included new-onset diabetes mellitus and renal failure as entities related to COVID-19 long-term spectrum [24]. Forest plots for specific symptoms are found in *Supplementary material (figures)*. Five (19%), 3 (11%), and 19 (70%) of meta-analyses reported low, substantial, and high heterogeneity, respectively. After outlier analysis, 11 (40%) pooled analysis shown low, 1 (4%) moderate, 6 substantial (22%), and 9 (33%) high heterogeneity (Table 3).

Meta-regression for modifiers of PACS prevalence

When evaluating modifying factors of PACS prevalence estimation, we found that age significantly raised prevalence estimation for fever, cough, and diarrhea within the evaluated manuscripts. Similarly, the proportion of female reported in the studies increased prevalence estimation of body aches, fever, and anosmia or hyposmia. Also, the prevalence estimation of arthralgias and red eye decreased with an increasing number of comorbidities. We also found that the general prevalence of PACS and cough increased according to the number of symptoms investigated by authors in each study, while the prevalence of asthenia and redeye decreased. Coefficients with 95% confidence intervals of the metaregression are shown in *Supplementary Material (Table 1)*.

**DISCUSSION** 

Prevalence and variety of long-term clinical manifestations of COVID-19 are not fully characterized. This analysis described the prevalence of 61 new or persistent manifestations after 21 days from the onset of COVID-19 symptoms and reported modifiers of prevalence estimation, which may influence PACS spectrum. To date, there is not an accepted period for establishing long-term complications. Some institutions such as the Centers for Disease Control and Prevention (CDC) in the USA propose four weeks to define the long-term effects

of COVID-19, while the guidelines of the National Institute for Health and Care Excellence (NICE) in England considers a more extended period of >12 weeks to classify the long-term manifestations. Notably, sequelae of COVID-19 persist for longer than six months and are higher than other respiratory infections, including influenza [41]. Definition of clinical stages during COVID-19 has proven to be challenging. However, Van Kampen, JJA et al, observed that shedding of SARS-CoV-2 virus has an average duration of 15 days, with a probability of <5% isolation of viable virus after three weeks from symptom onset. Based on this observation, a period of 21 days may reflect the conclusion of acute COVID-19 [42].

We found that 1 in 2 patients with COVID-19 will develop new or persistent clinical manifestations compatible with PACS. In a previous meta-analysis, Lopez-Leon S. et al. reported PACS prevalence as high as 80% [43]. In contrast, Taquet et al. found in a cohort of 273,618 COVID-19 survivors that 57% of patients had one or more long-COVID clinical manifestations during a 6-month period, although this number decreased to 36% after three months, this prevalence continues to be a large burden of long-term sequels [41]. Similar to our findings, Groff et al, reported a median PASC frequency at 1 month of 54.0% (45.0%-69.0%;); at 2-5 months, 55.0% (34.8%-65.5%); and at 6 or more months, 54.0% (31.0%-67.0%) [44]

Even though more reports are published on PACS, the heterogeneity of studies continues to limit the quality of evidence. In 19 (70%) of the pooled prevalence meta-analysis performed, heterogeneity was high; this large heterogeneity was expected first due to subjectivity involving specific clinical manifestations and second to the inability of standardized tools to evaluate some long-term manifestations. To deal with this high heterogeneity, an analysis to determine outlier manuscripts was performed, showing a 50% decrease of all high-level pooled prevalence analyses. This high heterogeneity could be explained to prevalence modifiers identified in the meta-regression analysis, including age, gender, comorbidities, and the number of evaluated symptoms [45]. By controlling sources of heterogeneity that

influence prevalence estimates for PACS and its manifestations, future studies are more likely to provide unbiased prevalence estimates of PACS, which may better inform the follow-up of patients after acute COVID-19.

Little is known about the clinical characteristics of patients who develop PACS. A report by the CDC indicates that nearly one of five out-setting patients with no comorbidities and age from 18-34 years did not return to usual health within three weeks of testing due to the persistence of symptoms [46]. Interestingly, Dennis et al. observed that 70% of the individuals at low risk of COVID-19 related mortality developed impairment in one or more organs in the following four months after the onset of symptoms; most of those patients were young women with a low prevalence of comorbidities and ambulatory treatment for COVID-19 [47]. These characteristics are opposite of what is described in acute COVID-19, in which comorbid men have a higher susceptibility to develop severe COVID-19 [48]. Notably, we found that the percentage of women reported in the manuscripts analyzed increased the prevalence of body aches, fever, anosmia, or hyposmia, while reported age, modified prevalence in an inverse relation for fever, cough, and diarrhea. Thus, intrinsic patient characteristics and the design of previous studies may contribute to gender and age differences.

Immunity-modulated gender disparities may contribute to the differences found in the prognosis of COVID-19 and PACS onset. The infection response process follows a series of steps that initiate with the entrance of the SARS-CoV-2 virus to cells by attaching to ACE-2 receptor and its posterior recognition by Toll-like receptors (TLR) 3, 7, 8, and 9, RIG-I and MDA5, with a subsequent triggering of type I interferon (I-IFN) response and NLRP3 inflammasome activation, these signals culminate in pyroptosis and inflammation response [49]. Some reports establish an internal capacity of some coronaviruses to diminish and delay I-IFN response, leading to increased viral replication and severe illness [50]. Likewise, it has been proposed that the imbalance of this normal response may culminate in other

disease manifestations such as multisystem inflammatory syndrome and post-acute COVID

syndrome. In addition, higher titles of anti-IFN antibodies are found in men compared to

women [51]. Thus, a more robust type I-IFN response in women and young individuals may

partially explain the better immunological response during acute COVID-19 and posterior

more adverse long-term effects in this population [52].

Precise estimates of PACS prevalence and its manifestations will be pivotal to planning

public health policies aimed at mitigating the long-term socio-economic impact of Long

COVID on public and private healthcare systems around the world [53]. Given the wide

spectrum of PACS on different body systems, a multidisciplinary approach will be required to

facilitate the recovery and rehabilitation of patients after COVID-19 [54]. Until now, there is

no specific treatment or management to treat PACS manifestations; however, recent data on

the impact of COVID-19 vaccinations on symptom recovery in PACS is promising and may

provide a viable pathway to reduce its burden despite the emergence of new SARS-CoV-2

variants or breakthrough infections [55–57]

Our study has several limitations. Available data were primarily extracted from observational

studies with no standardized symptoms in MEDLINE. Also, post-acute COVID-19 syndrome

definitions were not available, contributing to increased risks of bias. Results should be

interpreted with caution as high expected heterogeneity was found in most meta-analytic

results. Despite that, a strength of our study was the meta-regression analysis conducted to

explore for modifiers of prevalence estimates for post-acute COVID-19 syndrome. In

addition, our findings are similar to those previously reported. Comorbidities were not

available for eight manuscripts for meta-regression analysis, and one article did not specify

the proportion of women in the population.

Our findings may help standardize populations to study PACS after acute COVID-19 in

future studies and to provide better estimates of long-term manifestations, influencing PACS-

related public policy. Longitudinal studies on incident COVID-19 cases require standardized

approaches regarding the definition of PACS and long-term manifestations, consistent

follow-up times across studies and populations with diverse clinical spectrums of COVID-19

to better understand the incidence of PACS, its burden and the impact on patients and

healthcare systems. Data available on request from the authors.

Funding support: No specific founding was disclosed

Conflict of interest's disclosers: No conflict of interests was declared by the authors

## **REFERENCES**

- 1. Cohen PA, Hall LE, John JN, Rapoport AB. The Early Natural History of SARS-CoV-2 Infection. *Mayo Clinic Proceedings* 2020; **95**: 1124–6.
- 2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239.
- 3. WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021.
- 4. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. *BMC Neurol* 2011; **11**: 37.
- 5. Lam MH-B. Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory Syndrome Survivors: Long-term Follow-up. *Arch Intern Med* 2009; **169**: 2142.
- 6. Guillot X, Ribera A, Gasque P. Chikungunya-Induced Arthritis in Reunion Island: A Long-Term Observational Follow-Up Study Showing Frequently Persistent Joint Symptoms, Some Cases of Persistent Chikungunya Immunoglobulin M Positivity, and No Anticyclic Citrullinated Peptide Seroconversion After 13 Years. *J Infect Dis* 2020; **222**: 1740–4.
- 7. Clark DV, Kibuuka H, Millard M, *et al.* Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. *Lancet Infect Dis* 2015; **15**: 905–12.
- 8. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–15.
- 9. Langan D, Higgins JPT, Jackson D, *et al.* A comparison of heterogeneity variance estimators in simulated random  $\square$  effects meta  $\square$  analyses. *Res Syn Meth* 2019; **10**: 83–98.
- 10. Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis. *Res Synth Method* 2010; **1**: 112–25.
- 11. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Soft* 2010; **36**: 1–48.
- 12. Barón-Sánchez J, Santiago C, Goizueta-San Martín G, Arca R, Fernández R. Afectación del sentido del olfato y el gusto en la enfermedad leve por coronavirus (COVID-19) en pacientes españoles. *Neurología* 2020; **35**: 633–8.
- 13. Blair PW, Brown DM, Jang M, *et al.* The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study. *Open Forum Infectious Diseases* 2021; **8**: ofab007.
- 14. Boscolo-Rizzo P, Borsetto D, Fabbris C, *et al.* Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. *JAMA Otolaryngol Head Neck Surg* 2020; **146**: 729.
- 15. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020; **324**: 603.
- 16. Caronna E, Ballvé A, Llauradó A, *et al.* Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. *Cephalalgia* 2020; **40**: 1410–21.

- 17. Carvalho-Schneider C, Laurent E, Lemaignen A, *et al.* Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clinical Microbiology and Infection* 2021; **27**: 258–63.
- 18. Gambini G, Savastano MC, Savastano A, *et al.* Ocular Surface Impairment After Coronavirus Disease 2019: A Cohort Study. *Cornea* 2021; **40**: 477–83.
- 19. Garrigues E, Janvier P, Kherabi Y, *et al.* Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *Journal of Infection* 2020; **81**: e4–6.
- 20. Gerkin RC, Ohla K, Veldhuizen MG, *et al.* Recent Smell Loss Is the Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms. *Chemical Senses* 2021; **46**: bjaa081.
- 21. Halpin SJ, McIvor C, Whyatt G, *et al.* Postdischarge symptoms and rehabilitation needs in survivors of COVID 19 infection: A cross sectional evaluation. *J Med Virol* 2021; **93**: 1013–22.
- 22. Huang L, Zhao P, Tang D, *et al.* Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. *JACC: Cardiovascular Imaging* 2020; **13**: 2330–9.
- 23. Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, *et al.* Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. Madeddu G, ed. *PLoS ONE* 2020; **15**: e0243882.
- 24. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. *Int J Clin Pract* 2021; **75**: e13746.
- 25. Konstantinidis I, Delides A, Tsakiropoulou E, Maragoudakis P, Sapounas S, Tsiodras S. Short-Term Follow-Up of Self-Isolated COVID-19 Patients with Smell and Taste Dysfunction in Greece: Two Phenotypes of Recovery. *ORL J Otorhinolaryngol Relat Spec* 2020; **82**: 295–303.
- 26. Landi F, Carfi A, Benvenuto F, *et al.* Predictive Factors for a New Positive Nasopharyngeal Swab Among Patients Recovered From COVID-19. *American Journal of Preventive Medicine* 2021; **60**: 13–9.
- 27. Myall KJ, Mukherjee B, Castanheira AM, *et al.* Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. *Annals ATS* 2021; **18**: 799–806.
- 28. Niklassen AS, Draf J, Huart C, *et al.* COVID □19: Recovery from Chemosensory Dysfunction. A Multicentre study on Smell and Taste. *The Laryngoscope* 2021; **131**: 1095–100.
- 29. Park S, Lee C-W, Park D-I, *et al.* Detection of SARS-CoV-2 in Fecal Samples From Patients With Asymptomatic and Mild COVID-19 in Korea. *Clinical Gastroenterology and Hepatology* 2021; **19**: 1387-1394.e2.
- 30. Pellaud C, Grandmaison G, Pham Huu Thien HP, *et al.* Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area a retrospective cohort study. *Swiss Med Wkly* 2020; **150**: w20314.
- 31. Raman B, Cassar MP, Tunnicliffe EM, *et al.* Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine* 2021; **31**: 100683.
- 32. Sonnweber T, Sahanic S, Pizzini A, *et al.* Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. *Eur Respir J* 2021; **57**: 2003481.
- 33. Taboada M, Moreno E, Cariñena A, *et al.* Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. *British Journal of Anaesthesia* 2021; **126**: e110–3.
- 34. Tomasoni D, Bai F, Castoldi R, *et al.* Anxiety and depression symptoms after virological clearance of COVID 19: A cross sectional study in Milan, Italy. *J Med Virol* 2021; **93**: 1175–9.
- 35. Townsend L, Dowds J, O'Brien K, *et al.* Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. *Annals ATS* 2021; **18**: 997–1003
- 36. Townsend L, Dyer AH, Jones K, *et al.* Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. Madeddu G, ed. *PLoS ONE* 2020; **15**:

e0240784.

- 37. Vaira LA, Hopkins C, Petrocelli M, *et al.* Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study. *J Laryngol Otol* 2020; **134**: 703–9.
- 38. Villarreal IM, Morato M, Martínez-RuizCoello M, *et al.* Olfactory and taste disorders in healthcare workers with COVID-19 infection. *Eur Arch Otorhinolaryngol* 2021; **278**: 2123–7.
- 39. Weerahandi H, Hochman KA, Simon E, *et al.* Post-Discharge Health Status and Symptoms in Patients with Severe COVID-19. *J GEN INTERN MED* 2021; **36**: 738–45.
- 40. Zhao Y, Shang Y, Song W, *et al.* Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *EClinicalMedicine* 2020; **25**: 100463.
- 41. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. Kretzschmar MEE, ed. *PLoS Med* 2021; **18**: e1003773.
- 42. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, *et al.* Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021; **12**: 267.
- 43. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, *et al.* More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep* 2021; **11**: 16144.
- 44. Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Netw Open* 2021; **4**: e2128568.
- 45. Sudre CH, Murray B, Varsavsky T, *et al.* Attributes and predictors of long COVID. *Nat Med* 2021; **27**: 626–31.
- 46. Tenforde MW, Kim SS, Lindsell CJ, *et al.* Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network United States, March–June 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 993–8.
- 47. Dennis A, Wamil M, Alberts J, *et al.* Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open* 2021; **11**: e048391.
- 48. Brandi ML, Giustina A. Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. *Trends in Endocrinology & Metabolism* 2020; **31**: 918–27.
- 49. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021; 184: 861-80.
- 50. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. *Cell* 2021; **184**: 1671–92.
- 51. Bastard P, Rosen LB, Zhang Q, *et al.* Autoantibodies against type I IFNs in patients with lifethreatening COVID-19. *Science* 2020; **370**: eabd4585.
- 52. Brodin P. Immune determinants of COVID-19 disease presentation and severity. *Nat Med* 2021; **27**: 28–33.
- 53. Menges D, Ballouz T, Anagnostopoulos A, *et al.* Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. Simuunza MC, ed. *PLoS ONE* 2021; **16**: e0254523.
- 54. Wade DT. Rehabilitation after COVID-19: an evidence-based approach. *Clin Med* 2020; **20**: 359–65
- 55. Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France. *SSRN Journal* 2021.
- 56. Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. *Ann Intern Med* 2021; **174**: 1334–6.
- 57. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination

SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *The Lancet Infectious Diseases* 2021: S1473309921004606.

Figure 1. PRISMA flow diagram for search, screening, and manuscript selection.





Figure 2. Pooled prevalence estimates of long-term manifestations after acute COVID-

## **LONG-TERM MANIFESTATIONS AFTER ACUTE COVID-19**



\*Only reported in one manuscript. \*\*Continence involves both urinary and fecal continence. NDVA;

Near Distance Visual Acuity

Table 1. General and demographic characteristics of included studies.

Author	Country	Design	Sample size (N)	Gender (% female)	Mean age years (SD or IQR)	Population	Comorbidities	PACS symptoms	Clinical spectrum (systems involved)	Follow -up (days)
Konstantinidis, et al.	Greece	Cohort (prospective)	79	51	30.7 (5.3)	Ambulatory	Not specified	Nasal obstruction, olfactory and gustatory dysfunctions, rhinitis and, rhinorrhea.	Neurological Respiratory	30
Carvalho- Schneider, et al.	France	Cohort (prospective)	150	56	49 (15)	Ambulatory and hospitalized	0 comorbidities (46%), 1 comorbidity (35%), 2 comorbidities(19%)	Olfactory and gustatory dysfunctions, chest pain, diarrhea, weight loss, cutaneous signs, dyspnea, arthralgia, palpitations, fever, myalgia, cephalea, asthenia and vomiting.	Neurological Respiratory Musculoskeletal Gastrointestinal Cardiovascular Constitutional Cutaneous	30, 60
Kamal, et al.	Egypt	Cross- sectional	287	64	32.3(8.5)	Ambulatory and hospitalized	No comorbidities (70.7%), hypertension (7.7%), diabetes (5.2%), obesity (35.5%), dyslipidemia (1.4%), rheumatioid arthritis (1%), hypothyroidism (1%), asthma (1%), peptic ulcer (0.7%), arrhythmia (0.7%), smoking (9.8%)	Fatigue, anxiety, arthralgia, cephalea, chest pain, depression, dyspnea, new onset diabetes, blurred vision, tinnitus, fever, obsessive-compulsive disorder, migraine, stroke, renal failure, myocarditis, arrhythmia.	Constitutional Psychiatric Musculoskeletal Neurological Respiratory Endocrinological Cardiovascular Renal	21
Landi, et al.	Italy	Cohort (prospective)	131	39	55.8 (14.8)	Hospitalized	Hypertension (29%), COPD (9.1%), heart failure (6.1%), diabetes (5.3%), renal failure (3.1%), smoking (9.8%)	Fatigue, dyspnea, arthralgia, cough, red eye, rhinitis, cephalea, loss of appetite, sore throat, diarrhoea, and olfactory and gustatory dysfunctions.	Constitutional Respiratory Ocular Musculoskeletal Neurological Gastrointestinal	55
Garrigues, et al.	France	Cross- sectional	120	38	63.2 (15.7)	Hospitalized	Hypertension: (46.7%), overweight or obesity (47.5%), diabetes (21.7%)	Fatigue, dyspnea, memory loss, sleep disorders, attention disorder, hair loss, cough, chest pain,	Constitutional Respiratory Neurological Musculoskeletal	110

								and olfactory and gustatory dysfunctions.		
Tomasini, et al.	ltaly	Cross- sectional	105	27	55 (43-65)	Hospitalized	Not specified	Gastrointestinal symptoms, asthenia, anxiety, memory disorders, depression, burning pain, dyspnea, and olfactory and gustatory dysfunctions, chest pain, cephalea, constipation, tinnitus, insomnia, palpitations, NSTEMI, cough, and sore throat.	Constitutional Psychiatric Neurological Respiratory Gastrointestinal Musculoskeletal Cardiovascular	30-90
Carfi, et al.	ltaly	Cross- sectional	143	37	56.5 (16.6)	Hospitalized	Hypertension (35%), thyroid disease (18.2%), immune disorders (11.2%), COPD (9.1%), diabetes (7%), cardiovascular disease (4.9%), cancer (3.5%), atrial fibrillation (2.8%), heart failure (2.8%), renal failure (2.1%), stroke (1.4%), active smoking (10.5%)	Fatigue, dyspnea, arthralgias, chest pain, cough, anosmia, sicca syndrome, rhinitis, red eyes, dysgeusia, headache, sputum, lack of appetite, sore throat, vertigo, myalgia and diarrhea.	Constitutional Respiratory Musculoskeletal Neurological Gastrointestinal	60
Vaira, et al.	Italy	Cohort (prospective)	138	51	51.2 (8.8)	Ambulatory and hospitalized	Cardiovascular disease (26.8%), pulmonary disease (15.2%), diabetes (10.9%), obesity (29%)	Olfactory and gustatory dysfunction	Neurological	60
Halpin, et al.	UK	Cross- sectional	100	46	Ward patients: 70.5 (20-93) ICU: 58.5 (34-84)	Hospitalized	Hypertension (41%), obesity (24%), diabetes (29%), gastrointestinal disease (25%), cancer (28%), heart failure (5%), mental health condition (19%), osteoarthritis (13%), rheumatologic disease (14%), CKD (15%), immunosuppressive condition (15%), asthma (13%), neurologic disease (12%), COPD (8%), obstructive sleep apnea (7%), hyperlipidemia (4%), ischemic heart disease (10%), tachyarrhythmias	Fatigue, dyspnea, post- traumatic stress syndrome, concentration and memory alterations, anxiety/depression, pain or discomfort, cough, continence problems, dysphagia, voice changes, appetite problems, and diminished mobility.	Constitutional Respiratory Psychiatric Neurological Urological Gastrointestinal	48

							(12%), valvular heart disease (3%), venous thromboembolism (5%), thyroid disease (5%), gynecological disease (3%), hematological disease (10%), infectious disease (6%)			
Barón-Sánchez, et al.	Spain	Cross- sectional	31	61	44.6 (13.08)	Ambulatory	Not specified.	Hyposmia.	Neurological	38.47
Villarreal, et al.	Spain	Cohort (retrospectiv e)	230	85	43 (18-62)	Ambulatory and hospitalized	Not specified.	Olfactory dysfunctions	Neurological	30
Zhao, et al.	China	Cohort (retrospectiv e)	55	42	47.7 (15.49)	Hospitalized	Hypertension (10.91%), diabetes (3.64%), cardiovascular disease (3.64%), smoking (3.64%), others (3.64%).	Gastrointestinal symptoms, cephalea, fatigue, dyspnea, gustatory dysfunctions, cough, and sputum.	Gastrointestinal Neurological Constitutional Respiratory	64-93
Pellaud, et al.	Switzerla nd	Cohort (retrospectiv e)	196	N/E	70 (60-80)	Hospitalized	Hypertension (60%), diabetes (27%), obesity (21%), coronary heart disease (13%), sleep apnea syndrome (13%), cardiac insufficiency (11%), COPD (8%), cancer (8%), immunosuppression (5%), smoking (29%).	Asthenia, respiratory symptoms, olfactory and gustatory dysfunction.	Constitutional Respiratory Neurological	30
Boscolo-Rizzo, et al.	Italy	Cross- sectional	187	55	56 (20-89)	Ambulatory and hospitalized	Not specified.	Gustatory and olfactory dysfunction, cough, dyspnea, cephalea, congested nose, myalgias/arthralgias, loss of appetite, felt tired, sore throat, dizziness, diarrhea, sinonasal pain, abdominal pain, chest pain, fever, nausea.	Neurological Respiratory Musculoskeletal Constitutional Gastrointestinal	30
Park, et al.	Korea	Cohort (prospective)	46	46	26 (18-57)	Hospitalized	Reflux (13%), gastritis (6.5%), irritable bowel disease (6.5%), fatty liver (2.1%), others (6.5%).	Sputum, cough, rhinorrhea, cephalea, fatigue, chest pain, myalgia, nasal obstruction, anosmia, loss of appetite,	Respiratory Neurological Constitutional Musculoskeletal	52

								fever.		
Huang, et al.	China	Case-control	26	62	38 (32-45)	Hospitalized	Hypertension (8%)	Precordial chest pain, palpitations, chest distress.	Cardiovascular	47
Caronna, et al.	Spain	Cohort (prospective)	130	51	53.9 (16.4)	Ambulatory and hospitalized	Migraine (70%)	Cephalea.	Neurological	42
Townsend, et al.	Ireland	Cross- sectional	128	54	49.5 (15)	Ambulatory/ hospitalized	Anxiety/depression (7.8%)	Fatigue, not returning to full health.	Constitutional	42
Gambini, et al.	Italy	Cohort (prospective)	114	33	56.2 (14.2)	Hospitalized	Hypertension (43.8%), diabetes (26.6%), autoimmune disease (10.9%).	Reduction of near distance visual acuity, red eye	Ocular	60.3
Sonnweber, et al.	Austria	Cohort (prospective)	145	45	57 (14)	Ambulatory and hospitalized	Hypertension (30%), hypercholesterolemia (19%), diabetes (17%), cancer (12%), asthma (7%), CKD (7%), immunodeficiency (6%), COPD (6%), chronic liver disease (6%), interstitial lung disease (1%)	Dyspnea, sleep disorders, night sweet, pain, olfactory dysfunctions, cough, diarrhea/vomiting.	Respiratory Constitutional Neurological Gastrointestinal	60-100
Jacobs, et al.	USA	Cohort (prospective)	183	39	57 (48-68)	Hospitalized	Hypertension (47%), obesity (49.2%), overweight (36.1%), diabetes (28.4%), cardiac disease (27.9%), dyslipidemia (10.9%), asthma (10.4%), cancer (9.8%), immunodeficiency (4.4%), hypothyroidism (4.4%), psychiatric disorder (4.4%), COPD (3.8%), obstructive sleep apnea (3.3%), thromboembolic disease (1.6%).	Fatigue, dyspnea, cough, myalgias, cephalea, phlegm, ageusia, olfactory dysfunction, confusion, eye irritation, diarrhea, ulcers, fever.	Constitutional Respiratory Musculoskeletal Neurological Ocular Gastrointestinal Cutaneous	35
Taboada, et al.	Spain	Cohort (prospective)	91	35	64.5 (10.4)	Hospitalized	Hypertension (55.5%), dislipidemia (44%), obesity (38.5%), diabetes (23.1%), cardiomyopathy (20.9%), COPD (8.8%), asthma (6.6%).	Dyspnea, myalgias, asthenia, insomnia, arthralgias, cough, olfactory dysfunctions, chest pain	Respiratory Musculoskeletal Constitutional Neurological	180
Gerkin, et al.	USA	Cross-	4694	75*	40.6	Not specified	Diabetes (2%), heart disease	Olfactory dysfunctions,	Neurological	40

		sectional			(12)*		(0.3%), hypertension (8%), lung disease (0.5%), neurological disease (11%), obesity (1%), seasonal allergies (17%), smoking (63%), chronic sinus problems (3%), cancer (0.5%)	runny nose, sore throat, not recovered from respiratory symptom	Respiratory	
Blair, et al.	USA	Cohort (prospective)	118	57	56 (50-63)	Ambulatory and hospitalized	Hypertension (39%), smoking (26%), diabetes (16.1%), asthma or COPD (15.3%), solid tumor (15.3%), HIV (6.6%), hematologic malignancy (5.1%), CKD (3.4%), history of myocardial infarction (1.7%).	Fatigue, dry cough	Constitutional Respiratory	28-60
Niklassen, et al.	German y, Italy	Cohort (prospective)	111	46	44.5 (15)	Not specified	Not specified	Olfactory and gustatory dysfunctions.	Neurological	28, 45, 77-162
Raman, et al.	UK	Case-control	88	40	55.4 (13.2)*	Hospitalized	Hypertension (37.9%), asthma (34.5%), diabetes mellitus (15.5%) depression (5.2%), COPD (5.2%), coronary artery disease (3.4%), cerebrovascular disease (1.7%), previous cancer (3.4%).	Dyspnea, fatigue.	Respiratory Constitutional	60-90
Townsend, et al.	Ireland	Cross- sectional	153	57	48 (35-59)	Ambulatory and Hospitalized	Not specified	Fatigue, not returning to full health.	Constitutional	75
Myall, et al.	UK	Cohort (prospective)	35	71	60.5 (10.7)	Hospitalized	Hypertension (31.4%), Obesity (25.7%), diabetes (22.9%), asthma (22.9%), CKD (5.8%), COPD (5.8%), HIV (2.9%).	Functional deficit.	Respiratory	42
Weerahandi, et al.	USA	Cohort (prospective)	161	37	62 (50-67)	Hospitalized	Smoker (30.4%), CKD (8.1%), cancer (7.5%), arterial coronary disease (9.3%), diabetes (36.7%), cardiac failure (5%), hyperlipidemia (46.6%), hypertension (60.3%), asthma or COPD (24.2%), overweight (30.4%),	Dyspnea, diminished general health status, diminished physical health, diminished mental health.	Respiratory Psychiatric	37

			obesity (41%).		

<sup>\*</sup>From COVID-19 group.

Red eyes included: burning eye, foreign body sensation, watering eye, dry eye disease and eye irritation.

Olfactory dysfunctions include anosmia, hyposmia, dysosmia, phantosmia.

Gustatory dysfunctions include: ageusia, hypogeusia, dysgeusia

Olfactory and gustatory dysfunction include both olfactory and gustatory manifestations if they were reported together in the same article.

Chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), Human Immunodeficiency Virus (HIV).

(N/E) Not specified

Table 2. Pooled prevalence estimates of new or persistent manifestation after acute COVID-19

Symptom	Studies	Cases	Sample Size	Prevalence % (95 CI%)	I2 (%)	Symptom	Studies	Cases	Sample Size	Prevalence % (95 CI%)	l2 (%)
PACS (at least one persistent symptom)	15	2923	5586	56 (45-66)	98	Gastrointestinal manifestation	ons				
Constitutional manifestations						Dysphagia	1	8	100	8 (4; 15)	-
Fatigue	12	828	1534	49 (39; 58)	93	Diarrhea	5	59	774	7 (3; 12)	82
Asthenia	5	199	649	32 (22; 43)	89	Abdominal pain	1	2	187	1 (0; 4)	-
Night sweat	1	32	145	22 (16; 30)	-	Nausea	1	1	187	1 (0; 3)	-
Body aches	3	62	350	17 (11; 25)	68	Musculoskeletal manifestati	ons				
Tinnitus	1	48	287	17 (13; 22)	-	Myalgias	4	133	470	27 (17; 38)	84
Weakness	1	11	84	13 (7; 22)	-	Arthralgias	6	225	963	22 (15; 31)	88
Weight loss	1	13	150	9 (5; 14)	-	Chest pain	8	174	1050	13 (6; 23)	93
Loss of appetite	4	34	442	7 (5; 10)	2	Endocrinological manifestations					
Fever	5	45	853	4 (1; 8)	86	New onset diabetes	1	7	287	2 (1; 5)	-
Dizziness or vertigo	1	3	187	2 (0; 5)	-	Renal manifestations					
Neurological manifestations						Renal failure	1	4	287	1 (0; 4)	-
Hyposmia and dysgeusia	4	99	426	23 (10; 39)	92	Others					
Cephalea	8	240	1117	20 (13; 28)	89	Continence problems	1	10	100	10 (5; 18)	-
Anosmia or hyposmia	12	1747	4358	14 (4; 28)	99	Sleep disorders	3	103	356	29 (24; 34)	0
Ageusia or hypogeusia	4	77	591	12 (5; 22)	91	Voice changes	1	20	100	20 (13; 29)	-
Dysgeusia	3	19	269	7 (4; 11)	18	General health perception					
Migraine	1	8	287	3 (1; 5)	-	Diminished general health status.	2	169	281	60 (54; 66)	0
Cognitive disorders						Diminished mobility	1	37	100	37 (28;47)	-
Attention disorder	1	32	120	27 (19; 36)	-	Functional deficit	1	110	837	13 (11; 16)	-
Memory loss	3	77	325	23 (13; 34)	82	82 Respiratory manifestations					
Confusion	1	16	183	9 (5; 14)	-	Dyspnea	13	573	1733	35 (24; 46)	96

Concentration problems	1	22	100	22 (14; 31)	-	Sputum	3	54	284	20 (1; 51)	96
Psychiatric manifestations						Cough	8	192	965	19 (15; 24)	66
Anxiety	2	138	392	33 (24; 44)	73	Rhinitis**	4	51	372	16 (5; 30)	89
Post-traumatic	1	31	100	31 (22;41)	-	Sore throat	2	13	296	4 (2; 7)	0
Depression	2	93	392	19 (5; 39)	94	Sinonasal pain	1	3	187	2 (0; 5)	-
Obsessive-compulsive disorder	1	14	287	5 (3; 8)	-	Cardiovascular manifestation	าร				
Ocular manifestations						Myocardial edema	1	14	26	54 (33; 73)	-
Blurred vision	1	49	287	17 (13; 22)	-	Diastolic dysfunction	1	73	145	50 (42; 59)	-
Reduction in NDVA	1	18	114	16 (1; 24)	-	Chest distress	1	6	26	23 (9; 44)	-
Others (dry eye disease, sicca syndrome)	1	19	114	17 (1; 25)	-	Pericardial effusion	2	8	171	9 (0; 48)	95
Red eye*	3	55	406	14 (7-23)	80	Pulmonary hypertension	1	13	145	9 (5; 15)	-
Cutaneous manifestations						Stroke	1	8	287	3 (1; 5)	-
Hair loss	1	24	120	20 (13; 28)	-	Arrhythmias	1	1	287	0 (0; 2)	-
Cutaneous signs	1	21	150	14 (9; 21)	-	Myocarditis	1	4	287	1 (0; 4)	-
Ulcers	1	2	183	1 (0; 4)	-						
			-		_		-				$\rightarrow$

<sup>\*</sup>Red eye includes eye irritation, foreign body sensation, burning eye, watering eye
\*\*Rhinitis includes congested nose and runny nose.
Near Distance Visual Acuity (NDVA); Non-ST segment elevation myocardial infarction (NSTEMI)

Table 3. Outlier removing analysis of pooled prevalence estimates for PACS and individual long-term manifestations.

Symptom	Prevalence % (95 Cl%)	I2 (%)	Outlier studies excluded
PACS	53 (47-69)	82	7
Fatigue	48 (44-53)	41	4
Asthenia	36 (32-41)	0	1
Body aches	17 (11; 25)	68	0
Loss of appetite	7 (5-10)	2	0
Fever	2 (1;4)	0	1
Hyposmia and dysgeusia	29 (24-35)	0	1
Cephalea	20 (13; 28)	89	0
Anosmia or hyposmia	13 (9-17)	78	2
Ageusia or hypogeusia	8 (4-13)	59	1
Dysgeusia	7 (4-11)	18	0
Memory loss	18 (13-23)	0	1
Red eye*	14 (7-23)	80	0
Diarrhea	5 (3-7)	12	1
Myalgias	31 (21-42)	83	1
Arthralgias	26 (20-32)	75	1
Chest pain	15 (10-19)	51	2
Sleep disorders	29(24; 34)	0	0
Dyspnea	36 (29-43)	83	5
Sputum	7 (0-24)	89	1
Cough	18 (14-22)	55	1
Rhinitis**	9 (6-13)	0	1

<sup>\*</sup>Red eye includes eye irritation, foreign body sensation, burning eye, watering eye \*\*Rhinitis includes congested nose and runny nose.


# Supplementary table 1. Meta Regression for modifiers of prevalence estimates for PACS and individual long-term manifestations.


	% of Female gend	der	Number of comorbi	dities	Age		Number of symptoms	
Symptom	Coefficient (CI 95%)	P value	Coefficient (CI 95%)	P value	Coefficient (CI 95%)	P value	Coefficient (CI 95%)	P value
PACS	-0.0035 (-0.0122-0.0052)	0.425	0.0295 (-0.0111-0.0702 )	0.154	0.0016 (-0.0102- 0.0133)	0.793	0.0207 ( 0.0021-0.0394 )	0.030
Fatigue	0.0031 (-0.0079; 0.0141)	0.581	0.0016 (-0.0135; 0.0168)	0.8318	0.0020 (-0.0061; 0.0102)	0.625	-0.000 (-0.0177; 0.0177)	1.000
Asthenia	-0.0034 (-0.0145; 0.0077)	0.546	-	-	0.0059 (-0.0102; 0.0221)	0.472	-0.0195 (-0.0365; -0.0025)	0.025
Body aches	0.0075 (0.0014; 0.0137)	0.017	-	-	0.0038 (-0.0138; 0.0214)	0.673	0.0966 (-0.0991; 0.2923)	0.333
Loss of appetite	-0.0022 (-0.0114; 0.0070)	0.635	0.0024 (-0.0075; 0.0122)	0.633	0.0026 (-0.0013; 0.0065)	0.194	0.0007 (-0.0218; 0.0232)	0.952
Fever	0.0081 (0.0026; 0.0136)	0.004	-0.0029 (-0.0390; 0.0332)	0.874	-0.0050 (-0.0099; -0.0000)	0.049	0.0240 (-0.0057; 0.0538)	0.113
Hyposmia and dysgeusia	0.0080 (-0.0058; 0.0217)	0.254	-	-	-0.0091 (-0.0188; 0.0006)	0.067	0.0074 (-0.0265; 0.0412)	0.670
Anosmia or hyposmia	0.0101 (0.0045; 0.0158)	<0.001	0.0099 (-0.0450; 0.0648)	0.723	-0.0027 (-0.0159; 0.0106)	0.695	-0.0044 (-0.0355; 0.0266)	0.778
Ageusia or hypogeusia	0.0066 (-0.0125; 0.0256)	0.499	0.0026 (-0.0186; 0.0239)	0.809	-0.0066 (-0.0342; 0.0209)	0.636	0.0172 (-0.0093; 0.0437)	0.203
Dysgeusia	0.0008 (-0.0137; 0.0154)	0.912	-	-	0.0114 (-0.0082; 0.0309)	0.254	0.0205 (-0.0058; 0.0468)	0.127
Cephalea	0.0078 (-0.0017; 0.0173)	0.108	-0.011 (-0.0315; 0.0095)	0.292	-0.0061 (-0.0136; 0.0013)	0.107	-0.0043 (-0.0237; 0.0151)	0.664
Dyspnea	-0.0064 (-0.0188; 0.0060)	0.312	0.0022 (-0.0157; 0.0201)	0.808	0.0128 (-0.0001; 0.0258)	0.052	-0.0210 (0.0467; 0.0047)	0.109
Cough	0.0015 (-0.0063; 0.0094)	0.698	-0.0042 (-0.0208; 0.0124)	0.620	-0.0064 (-0.0113; -0.0015)	0.011	0.012 (0.0005; 0.0236)	0.041
Sputum	0.0697 (-0.0677; 0.2072)	0.320	-0.020 (-0.112; 0.072)	0.671	-0.0175 (-0.0431; 0.0082)	0.183	0.0399 (-0.1094; 0.1893)	0.600
Rhinitis*	-0.0093 (-0.0459; 0.0273)	0.619	-	-	-0.0079 (-0.0176; 0.0018)	0.110	0.0038 (-0.0360; 0.0435)	0.853
Diarrhea	0.0079 (-0.0020; 0.0178)	0.117	0.0006 (-0.0299; 0.0.0310)	0.971	-0.025 (-0.0396; -0.0104)	<0.001	-0.0091 (-0.0557; 0.0375)	0.702
Myalgias	0.0010 (-0.0168; 0.0189)	0.909	0.0062 (-0.0342; 0.0465)	0.764	0.0058 (-0.0027; 0.0142)	0.184	-0.0158 (-0.0723; 0.0407)	0.584
Arthralgias	-0.0013 (-0.0112; 0.0086)	0.794	-0.0199 (-0.0388; -0.0010)	0.039	-0.0009 (-0.0110; 0.0091)	0.854	-0.0038 (-0.0279; 0.0203)	0.759
Chest pain	0.0018 (-0.0102; 0.0137)	0.772	0.0148 (-0.0070-0.0367)	0.184	-0.0047 (-0.0125; 0.0031)	0.241	-0.0018 (-0.0309; 0.0273)	0.903

Red eye**	-0.0230 (-0.0528; 0.0068)	0.130	-0.0165 (-0.0267; -0.0062)	0.002	-0.1093 (-0.3159; 0.0973)	0.300	-0.0151 (-0.0278; -0.0025)	0.019
Sleep disorders	-0.0057 (-0.0179; 0.0065)	0.361	-0.0065 (-0.0216; 0.0085)	0.394	0.0067 (-0.0076; 0.0209)	0.357	-0.0139 (-0.0733; 0.0455)	0.646
Memory loss	0.0017 (-0.0207; 0.0240)	0.8846	-	-	0.0012 (-0.0264; 0.0289)	0.931	0.1041 (-0.2078; 0.4160)	0.513

<sup>\*</sup>Red eye included: eye irritation, foreign body sensation, burning eye, watering eye \*\*Rhinitis included: congested nose and runny nose.

Supplementary figures. Forest plots of long-term manifestation pooled prevalence estimates.























































57

Study	Events	Total	Anosi	mia a	nd hy	oosmi	ia	Proportion	95%-CI	Weight (fixed)	Weight (random)
Niklassen, et al.	1	93	:			;		0.01	[0.00; 0.06]	2.1%	8.3%
Vaira, et al.	8	138						0.06	[0.03; 0.11]	3.2%	8.4%
Tomasini, et al.	6	105						0.06	[0.02; 0.12]	2.4%	8.4%
Jacobs, et al.	17	183	<del></del>			1		0.09	[0.06; 0.14]	4.2%	8.5%
Park, et al.	4	46				į		0.09	[0.02; 0.21]	1.1%	8.1%
Taboada, et al.	10	91		_				0.11	[0.05; 0.19]	2.1%	8.3%
Garrigues, et al.	16	120						0.13	[0.08; 0.21]	2.8%	8.4%
Landi, et al.	16	109						0.15	[0.09; 0.23]	2.5%	8.4%
Sonnweber, et al.	26	145	÷	+		1		0.18	[0.12; 0.25]	3.3%	8.4%
Barón-Sánchez, et al. []	7	31	<del>-</del>	-		÷		0.23	[0.10; 0.41]	0.7%	7.9%
Carvalho-Schneider, et al.	40	150		_	•—			0.27	[0.20; 0.34]	3.4%	8.4%
Gerkin, et al.	1596	3147					+	0.51	[0.49; 0.52]	72.1%	8.6%
Fixed effect model		4358				<b>\$</b>			[0.37; 0.40]		
Random effects model Heterogeneity: $I^2 = 99\%$ , $\tau^2 = 100$	= 0.0892, į	p < 0.01		$\overline{}$				0.14	[0.04; 0.28]		100.0%
			0.1	0.2	0.3	0.4	0.5				

Study	Events	Total	Ageusia or hypogeusia	Proportion	95%-CI	(fixed)	(random)
Vaira, et al.	6	138 -		0.04	[0.02; 0.09]	23.4%	24.9%
med Rxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint	18	183		0.10	[0.06; 0.15]	30.9%	25.5%
It is made available under a CC-BY-NC 4.0 International license.	13	120		0.11	[0.06; 0.18]	20.3%	24.5%
Carvalho-Schneider, et al.	40	150		0.27	[0.20; 0.34]	25.4%	25.1%
Fixed effect model		591		0.12	[0.09; 0.15]	100.0%	
Random effects model Heterogeneity: $I^2 = 91\%$ , $\tau^2 =$	= 0.0169,	p < 0.01		0.12	[0.05; 0.22]		100.0%

0.05 0.1 0.15 0.2 0.25 0.3

Study	Events	Total	Ancemia and hyposmia	Proportion		Weight (fixed)	Weight (random)
Nikieses, et al.	1	93			man-nass	2.1%	8.3%
					10,03, 0,110	3.2%	8.4%
Tormonini, et al.	- 6	105		0.06	10.02: 0.155	2.4%	8.4%
Jacobs, et al.	17	153		0.00	10.08.0.140	4.2%	8.5%
Park, ct pl.	4	46		0.05	10.02: 0.215	1.1%	8.1%
Toboxia et al.	50	91		0.11	10.05 0.160	2.1%	8.3%
Cartoues, et al.	16	120		0.13	D.GE D.21	2.8%	2.4%
Landi, et al.	. 59	109		0.15	10.09 0.20	2.5%	8.4%
Sonoveber et al.	26	146	-	0.18	ID 12: D 260	3.2%	8.4%
Bartin-Sánchez, et al. []	7	31			(0.10, 0.41)	0.2%	7.9%
Coveho-Schneider, et al.	4)	150		0.27	10.20: p.340	3.4%	8.4%
Cercn, et al.	1506	2547		E 0.51	[0.49; 0.52]	72.1%	5.6%
Fixed effect model		4358		9.28	19.37: 0.460	100.0%	
Random effects model			-	9.14	19.04: 0.281		100.0%
Hotomporary; I' a 85%, v' a	c reno	6402					
				0.5			

Study	Events	Total		Anxi	iety		Proportion	95%-CI	Weight (fixed)	Weight (random)
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265125, this version posted October 18, 2021. The copyright holder for	this preprint	105 —	-	-			0.28	[0.19; 0.37]	26.8%	43.7%
It is made available under a CC-BY-NC 4.0 International license.	109	287				•	- 0.38	[0.32; 0.44]	73.2%	56.3%
Fixed effect model		392					0.35	[0.30; 0.40]	100.0%	
Random effects mode Heterogeneity: $I^2 = 73\%$ ,		3, p = 0.06					- 0.33	[0.24; 0.44]		100.0%
		0.2	0.25	0.3	0.35	0.4				

Study	Events	Total	Arthralgias	Proportion	95%-CI	Weight (fixed)	Weight (random)
Carvalho-Schneider, et al.	13	150 -		0.09	[0.05; 0.14]	15.6%	16.8%
Jacobs, et al.	29	183		0.16	[0.11; 0.22]	19.0%	17.1%
med Rxiv preprint doi: htt s://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: htt s://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: https://www.new.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: https://www.new.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: https://www.new.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: https://www.new.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: https://www.new.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which preprint doi: https://www.new.org/10.1101/2021.10.10.1101/2021.10.10.1101/2021.10.1101/2021.10.10.1101/2021.10.10.1101/2021.10.10.1101/2021.10.10.10.10.10.10.10.10.10.10.10.10.10	28	109		0.26	[0.18; 0.35]	11.3%	16.1%
It is made available under a CC-BY-NC 4.0 International license.	39	143		0.27	[0.20; 0.35]	14.9%	16.7%
Taboada, et al.	26	91	- 11 II	0.29	[0.20; 0.39]	9.5%	15.6%
Kamal, et al.	90	287		0.31	[0.26; 0.37]	29.8%	17.8%
Fixed effect model		963		0.23	[0.20; 0.25]	100.0%	
Random effects model Heterogeneity: $I^2 = 88\%$ , $\tau^2 =$	0.0122,	p < 0.01		0.22	[0.15; 0.31]		100.0%

0.05 0.1 0.15 0.2 0.25 0.3 0.35

Study	Events	Total	Asthenia	Proportion	95%-CI	Weight (fixed)	Weight (random)
Boscolo-Rizzo, et al.	29	187		0.16	[0.11; 0.22]	28.8%	20.9%
Tomasini, et al.	33	105		0.31	[0.23; 0.41]	16.2%	19.6%
medRxiv preprint doi; https://colorg/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright helder for this preprint (which was not ser fried by piece eview) is the author/funcer, who has granted necessary display the preprint in perpetuity.  It is made available under a CC-bY-1 D was method and reemse.	54	150		0.36	[0.28; 0.44]	23.1%	20.4%
Taboada, et al.	34	91		0.37	[0.27; 0.48]	14.0%	19.2%
Pellaud, et al.	49	116		0.42	[0.33; 0.52]	17.9%	19.9%
Fixed effect model		649		0.30	[0.27; 0.34]	100.0%	-
Random effects model Heterogeneity: $I^2 = 89\%$ , $\tau^2 =$	0.0151,	o < 0.01			[0.22; 0.43]		100.0%

Study	Events	Total	Body_aches	Proportion	95%-CI	(fixed)	Weight (random)
Tomasini, et al.	11	105 —		0.10	[0.05; 0.18]	30.0%	32.4%
med Rxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265 23; this version posted October 18, 2021. The copyright holder for this provided in the copyright holder for the copyright holder for the copyright holder for this provided in the copyright holder for the cop	reprint ty. 19	100		0.19	[0.12; 0.28]	28.6%	31.8%
Sonnweber, et al.	32	145		0.22	[0.16; 0.30]	41.4%	35.8%
Fixed effect model		350		0.17	[0.14; 0.22]	100.0%	
Random effects model Heterogeneity: I <sup>2</sup> = 68%, τ		5, p = 0.05	0.1 0.15 0.25	0.17	[0.11; 0.25]		100.0%

0.1 0.15 0.2 0.25

Study	Events	Total	Cephalea	Proportion	95%-CI	Weight (fixed)	Weight (random)
Boscolo-Rizzo, et al.	19	187		0.10	[0.06; 0.15]	16.7%	13.3%
Landi, et al.	11	109		0.10	[0.05; 0.17]	9.8%	12.6%
Jacobs, et al.	23	183		0.13	[0.08; 0.18]	16.4%	13.2%
medRxiv preprint doi: https://doi.org/10.1101/2021.t0.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	10	55	- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.18	[0.09; 0.31]	5.0%	11.2%
(which was not certified by peer review) is the author/funder, who has granted medically a license to display the preprint in perpetuity.  It is made available under a CC-BY-NC 4.0 International license.	12	46	- <del>1</del>	0.26	[0.14; 0.41]	4.1%	10.7%
Caronna, et al.	28	100		0.28	[0.19; 0.38]	9.0%	12.4%
Kamal, et al.	83	287		0.29	[0.24; 0.35]	25.6%	13.6%
Carvalho-Schneider, et al.	54	150		0.36	[0.28; 0.44]	13.4%	13.0%
Fixed effect model		1117		0.21	[0.18; 0.23]	100.0%	
Random effects model Heterogeneity: $I^2 = 89\%$ , $\tau^2 =$	= 0.0156,	p < 0.0°		0.20	[0.13; 0.28]		100.0%
			0.1 0.2 0.3 0.4				

Study	Events	Total	Chest_pain	Proportion	95%-CI	Weight (fixed)	Weight (random)
Boscolo-Rizzo, et al.	2	187 ⊪		0.01	[0.00; 0.04]	17.8%	13.2%
Taboada, et al.	8	91		0.09	[0.04; 0.17]	8.7%	12.6%
Garrigues, et al.	13	120		0.11	[0.06; 0.18]	11.4%	12.9%
mearXiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which was not certify by neer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	3	26	- 10 (1) - 10 (1)	0.12	[0.02; 0.30]	2.5%	10.3%
It is made available under a CC-BY-NC 4.0 International license.	7	46		0.15	[0.06; 0.29]	4.4%	11.6%
Carvalho-Schneider, et al.	27	150		0.18	[0.12; 0.25]	14.3%	13.0%
Carfi, et al.	31	143	1	0.22	[0.15; 0.29]	13.6%	13.0%
Kamal, et al.	83	287		0.29	[0.24; 0.35]	27.3%	13.4%
Fixed effect model		1050		0.00 0.000 00	[0.12; 0.17]	100.0%	
Random effects model Heterogeneity: $I^2 = 93\%$ , $\tau^2 =$	0.0276,	p < 0.01		0.13	[0.06; 0.23]		100.0%

0.05 0.1 0.15 0.2 0.25 0.3

Study	Events	Total	Cough	Proportion	95%-CI	(fixed)	Weight (random)
Blair, et al.	11	84 -		0.13	[0.07; 0.22]	8.7%	11.3%
Taboada, et al.	13	91		0.14	[0.08; 0.23]	9.4%	11.7%
Landi, et al.	16	109		0.15	[0.09; 0.23]	11.3%	12.5%
mean xiv preprint doi: https://doi.olg/10.1101/202110.17.21.65123, this version posted October 18, 2021. The copyright holder for	r this preprint	145		0.16	[0.10; 0.23]	15.0%	13.7%
It is made available under a CC-BY-NC 4.0 International license.	20	120	MATERIAL AND ADDRESS OF THE PARTY OF T	0.17	[0.10; 0.25]	12.4%	12.9%
Boscolo-Rizzo, et al.	46	187		0.25	[0.19; 0.31]	19.3%	14.7%
Jacobs, et al.	46	183		0.25	[0.19; 0.32]	18.9%	14.6%
Park, et al.	17	46	1 1 1	0.37	[0.23; 0.52]	4.8%	8.5%
Fixed effect model		965		0.20	[0.17; 0.22]	100.0%	
Random effects model Heterogeneity: I <sup>2</sup> = 66%, τ		1, p < 0.0			[0.15; 0.24]		100.0%
			0.1 0.2 0.3 0.4	0.5			

Study	Events	Total		Depression	Proportion	95%-CI	(fixed)	Weight (random)
medRxiv preprint doi. https://doi.org/10.1101/2021.10.17.21205123, this version posted October 18, 2021. The copyright holder for this (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpet	preprint uity.	105 —	100			[0.05; 0.18]		48.6%
Kamal, et al.	82	287			- 0.29	[0.23; 0.34]	73.2%	51.4%
Fixed effect model		392			0.23	[0.19; 0.27]	100.0%	
Random effects model Heterogeneity: I <sup>2</sup> = 94%, 1		6, p < 0.0	1		0.19	[0.05; 0.39]		100.0%
		Mitthi	0.05.450.00.00.00.00.00	0.15 0.2 0.25 0.3				

Study	Events	Total	Diarrhea	Proportion	95%-CI	Weight (fixed)	Weight (random)
Jacobs, et al.	7	183		0.04	[0.02; 0.08]	23.6%	20.7%
Landi, et al.	4	109		0.04	[0.01; 0.09]	14.1%	18.7%
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint the few controls of the copyright holder for this preprint the copyright holder for the copyri	10	187		0.05	[0.03; 0.10]	24.1%	20.7%
Sonnweber, et al.	12	145		0.08	[0.04; 0.14]	18.7%	19.9%
Carvalho-Schneider, et al.	26	150		0.17	[0.12; 0.24]	19.4%	20.0%
Fixed effect model		774		0.07	[0.05; 0.09]	100.0%	
Random effects model Heterogeneity: $I^2 = 82\%$ , $\tau^2 =$	0.0074,	p < 0.01			[0.03; 0.12]		100.0%

0.05 0.1 0.15 0.2

			Diminis	shed_ge	eneral			Weight	Weight
Study	Events	Total		health_	status	Proportion	95%-CI	(fixed)	(random)
medRxiv preprint doi: https://doi.org/10.1101/2021.10 17.21265123; this version posted October 18, 2021. The copyright holds (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint	for this preprint	128 —		1000 1000		0.58	[0.49; 0.66]	45.6%	45.6%
Townsend, et al.	95	153				0.62	[0.54; 0.70]	54.4%	54.4%
Fixed effect model		281		!		0.60	[0.54; 0.66]	100.0%	
Random effects mode Heterogeneity: $I^2 = 0\%$ , $\tau$		).47				0.60	[0.54; 0.66]		100.0%
\$350; ipinis 257	535355	0.	5 0.55	0.6	0.65				

Study	Events Total	Dysgeusia	Proportion	95%-CI	Weight (fixed)	Weight (random)
Zhao, et al.	2 55		0.04	[0.00; 0.13]	20.5%	22.3%
nedRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265128; this version posted October 18, 2021. The copyright holder for (winch was not sertines by peer re wev) is the author/funde, who has granted medRxiv a license to display the preprint in pellt is made available enter: CC-Bit NC 410 International license.	his preprint petuity. 6 105		0.06	[0.02; 0.12]	39.0%	38.3%
Landi, et al.	11 109			[0.05; 0.17]		39.4%
Fixed effect model	269			[0.04; 0.10]	100.0%	40000
Random effects mode	Mar.		0.07	[0.04; 0.11]		100.0%
Heterogeneity: $I^2 = 18\%$ ,	$\tau^- = 0.0006, p = 0.$	0.05 0.1	0.15			

						Weight	Weight
Study	Events	Total	Dyspnea	Proportion	95%-CI	(fixed)	(random)
Tomasini, et al.	7	105		0.07	[0.03; 0.13]	6.1%	7.7%
Carvalho-Schneider, et al.	16	150		0.11	[0.06; 0.17]	8.7%	7.8%
Zhao, et al.	8	55		0.15	[0.06; 0.27]	3.2%	7.3%
Boscolo-Rizzo, et al.	30	187		0.16	[0.11; 0.22]	10.8%	7.8%
Kamal, et al.	81	287		0.28	[0.23; 0.34]	16.5%	7.9%
Jacobs, et al.	58	183	100 mm to 100 mm	0.32	[0.25; 0.39]	10.5%	7.8%
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (twinch trais not sert ries b) peer review is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. I is made available under a CC-BY-MS-1.0 International license.	49	145		0.34	[0.26; 0.42]	8.4%	7.8%
Garrigues, et al.	50	120		0.42	[0.33; 0.51]	6.9%	7.7%
Carfi, et al.	62	143	1 10000 1 10000	0.43	[0.35; 0.52]	8.2%	7.8%
Landi, et al.	50	109		0.46	[0.36; 0.56]	6.3%	7.7%
Halpin, et al.	50	100		0.50	[0.40; 0.60]	5.8%	7.7%
Raman, et al.	36	58		0.62	[0.48; 0.74]	3.4%	7.4%
Taboada, et al.	76	91		0.84	[0.74; 0.90]	5.3%	7.6%
Fixed effect model		1733		0.32	[0.30; 0.34]	100.0%	
Random effects model					[0.24; 0.46]		100.0%
Heterogeneity: $I^2 = 96\%$ , $\tau^2 =$	0.0444,	p < 0.0					

0.2 0.4 0.6 0.8

						Weight	Weight
Study	Events	Total	Fatigue	Proportion	95%-CI	(fixed)	(random)
Zhao, et al.	9	55		0.16	[0.08; 0.29]	3.6%	7.7%
Park, et al.	11	46		0.24	[0.13; 0.39]	3.0%	7.5%
Halpin, et al.	36	100		0.36	[0.27; 0.46]	6.5%	8.3%
Jacobs, et al.	82	183		0.45	[0.37; 0.52]	11.9%	8.7%
Townsend, et al.	73	153		0.48	[0.40; 0.56]	10.0%	8.6%
ThearXxv preprint abi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for th	56	109		0.51	[0.42; 0.61]	7.1%	8.4%
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpentities made available under a CC-BY-NC 4.0 International license.	30	58		0.52	[0.38; 0.65]	3.8%	7.8%
Townsend, et al.	67	128	90000 90000	0.52	[0.43; 0.61]	8.3%	8.5%
Carfi, et al.	76	143		0.53	[0.45; 0.62]	9.3%	8.6%
Garrigues, et al.	66	120			[0.46; 0.64]	7.8%	8.5%
Tolba, et al.	209	287			[0.67; 0.78]	18.7%	8.8%
Weerahandi, et al.	113	152		그렇지 이 이 아이를 보고 있었다.	[0.67; 0.81]	9.9%	8.6%
Fixed effect model		1534		0.54	[0.52; 0.57]	100.0%	
Random effects model					[0.39; 0.58]		100.0%
Heterogeneity: $I^2 = 93\%$ , $\tau^2 = 0.0247$ , $p < 0.01$							
		M 1976 200	0.1 0.2 0.3 0.4 0.5 0.6 0.7	0.8			

Study	Events	Total	Fever	Proportion	95%-CI	Weight (fixed)	Weight (random)
Jacobs, et al.	2	183		0.01	[0.00; 0.04]	21.4%	21.1%
Boscolo-Rizzo, et al.	5	187		0.03	[0.01; 0.06]	21.9%	21.1%
medRxiv pre-print doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (whiten was not certified by peer refreed is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  It is made available under a CC-BY-NC 4.0 International license.	1	46		0.02	[0.00; 0.12]	5.4%	15.2%
Carvalho-Schneider, et al.	5	150		0.03	[0.01; 0.08]	17.6%	20.5%
Kamal, et al.	32	287		- 0.11	[0.08; 0.15]	33.6%	22.1%
Fixed effect model		853		0.04	[0.03; 0.06]	100.0%	
Random effects model Heterogeneity: $I^2 = 86\%$ , $\tau^2 =$	0.0091,	o < 0.0°			[0.01; 0.08]		100.0%
			0.02 0.06 0.10.12				

Study	Events	Total	Hyposmia and dysgeusia	Proportion	95%-CI	(fixed)	Weight (random)
Pellaud, et al.	7	116		0.06	[0.02; 0.12]	27.2%	26.0%
medRxiv preprint dol. https://doi.olg/10.1101/2021.10.11.21265123; this version posted October 18, 2021. The copyright holder for this	preprint 23	93		0.25	[0.16; 0.35]	21.8%	25.6%
It is made available under a CC-BY-NC 4.0 International license .  BOSCOO-RIZZZO, EL a	58	187		0.31	[0.24; 0.38]	43.8%	26.7%
Konstantinidis, et al.	11	30		- 0.37	[0.20; 0.56]	7.1%	21.8%
Fixed effect model		426		0.22	[0.18; 0.26]	100.0%	
Random effects mode Heterogeneity: I <sup>2</sup> = 92%, 1		, p < 0.	.01		[0.10; 0.39]		100.0%
			0.1 0.2 0.3 0.4 0.5				

Study	Events	Total		Loss_of_appetite	Proportion	95%-CI	(fixed)	Weight (random)
Park, et al.	1	46 -	- 101		0.02	[0.00; 0.12]	10.5%	10.7%
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265125, trills version pusted October 18, 2021. The copyright holder for this	preprint	187			0.07	[0.04; 0.12]	42.2%	41.8%
It is made available under a CC-BY-NC 4.0 International license.	8	100			0.08	[0.04; 0.15]	22.6%	22.8%
Landi, et al.	11	109			<del>-</del> 0.10	[0.05; 0.17]	24.7%	24.8%
Fixed effect model		442			0.07	[0.05; 0.10]	100.0%	
Random effects model					0.07	[0.05; 0.10]		100.0%
Heterogeneity: $I^2 = 2\%$ , $\tau^2$	< 0.0001,	p = 0.38				100 S150		

0.05 0.1 0.15

Study	Events	Total	Memory loss	Proportion	95%-CI	Weight (fixed)	Weight (random)
Tomasini, et al.	18	105 —		0.17	[0.10; 0.26]	32.3%	33.2%
med Rxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint in perpetuity. It is made available and a CC-BY-NC 4.0 International license.	18	100 -		0.18	[0.11; 0.27]	30.8%	32.9%
Garrigues, et al.	41	120		0.34	[0.26; 0.43]	36.9%	34.0%
Fixed effect model		325	:1	0.23	[0.19; 0.28]	100.0%	
Random effects model				0.23	[0.13; 0.34]		100.0%
Heterogeneity: $I^2 = 82\%$ , $\tau^2$	= 0.0103	3, p < 0.0					

0.15 0.2 0.25 0.3 0.35 0.4

Study	Events	Total	Myalgias	Proportion	95%-CI	(fixed)	(random)
Park, et al.	6	46 -		0.13	[0.05; 0.26]	9.9%	20.9%
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this preprint (which were not display the granted modRyin a license to display the propriet in persectivity.	39	183		0.21	[0.16; 0.28]	38.9%	27.4%
Carvalno-Schnelder, et al.	54	150		0.36	[0.28; 0.44]	31.9%	26.8%
Taboada, et al.	34	91		- 0.37	[0.27; 0.48]	19.4%	24.8%
Fixed effect model		470		0.28	[0.24; 0.32]	100.0%	
Random effects model Heterogeneity: $I^2 = 84\%$ , $\tau^2 =$	0.0116,	p < 0.01		0.27	[0.17; 0.38]		100.0%

0.1 0.2 0.3 0.4

Study	Events	Total	PACS prevalence	Proportion	95%-CI	Weight (fixed)	Weight (random)
Vaira, et al.	10	138		0.07	[0.04; 0.13]	2.5%	6.8%
Barón-Sánchez, et al. []	7	31		0.23	[0.10; 0.41]	0.6%	5.9%
Konstantinidis, et al.	11	30		0.37	[0.20; 0.56]	0.5%	5.9%
Sonnweber, et al.	55	145		0.38	[0.30; 0.46]	2.6%	6.8%
Myall, et al.	325	837		0.39	[0.36; 0.42]	15.0%	7.0%
Gerkin, et al.	1596	3147			[0.49; 0.52]	56.3%	7.0%
medRxiv preprint doi: http://co.orgid.com/2025.com/p.ir/24.2051.3; this version prested Optober 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted med Rxiv a cense to display the preprint in perpetuity.  It is not a available under a CC-BY-UC at 0 International license.	55	105			[0.42; 0.62]	1.9%	6.7%
Caronna, et al.	55	100		0.55	[0.45; 0.65]	1.8%	6.7%
Gambini, et al.	64	114		0.56	[0.47; 0.65]	2.0%	6.7%
Pellaud, et al.	73	116		0.63	[0.53; 0.72]	2.1%	6.7%
Carvalho-Schneider, et al.	102	150		(M.M.S.S.M.)	[0.60; 0.75]	2.7%	6.8%
Weerahandi, et al.	113	152		1969/1920/19	[0.67; 0.81]	2.7%	6.8%
Taboada, et al.	76	91		3930 Sin	[0.74; 0.90]	1.6%	6.6%
Carfi, et al.	125	143			[0.81; 0.92]	2.6%	6.8%
Tolba, et al.	256	287			[0.85; 0.93]	5.1%	6.9%
Fixed effect model		5586		0.53	[0.51; 0.54]	100.0%	
Random effects model					[0.45; 0.66]		100.0%
Heterogeneity: $I^2 = 98\%$ , $\tau^2 =$	0.0429,	o < 0.0	0.2 0.4 0.6 0.8				

Study	Events Total	Pericardial_efussion	Proportion	95%-CI	Weight (fixed)	Weight (random)
metric preprint doi: https://doi.olg/10.110v/2021.10.17.21 65123, this version posted October 18, 2021. The copyright holder for (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in It is made available under a CC-BY-NC 4.0 International license.	This preprint perpetuity.  1 145 7 26			[0.00; 0.04] [0.12; 0.48]		51.9% 48.1%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 95\%$ , 1		0.1 0.2 0.3 0.4		[0.00; 0.05] [0.00; 0.48]	100.0%	100.0%

Study	Events Total	Red_eye	Proportion		Weight (fixed)	Weight (random)
Jacobs, et al.	15 183 —		0.08 [0	0.05; 0.13]	45.0%	35.4%
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for (which was not certified by peer review) is the author funder, who has granted medRxiv a license to display the preprint in periods and a constant ender a CC-BY-NC 4.0 International license.	this preprint erpetuity.		0.15 [0	0.09; 0.23]	26.9%	32.1%
Gambini, et al.	24 114		0.21 [0	0.30]	28.1%	32.5%
Fixed effect model	406		0.13 [0	.10; 0.17]	100.0%	
Random effects mode			0.14 [0	.07; 0.23]	-	100.0%
Heterogeneity: $I^2 = 80\%$ ,	$\tau^2 = 0.0076, p < 0.01$					
	0.05	0.1 0.15 0.2 0.25				

Study	Events	Total	Rhinitis	S		Proportion	95%-CI	Weight (fixed)	Weight (random)
mearxiv preprint doi: https://doi.org/10.1101/2021.10.17.27265123, this version posted October 18, 2021. The copyright holder for this (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpertit is made available under a CC-BY-NC 4.0 International license.	2 16 preprint uity.	30 - 187				0.09	[0.01; 0.22] [0.05; 0.14]	50.1%	27.5%
Landi, et al. Park, et al.	13 20	109 46		- 100			[0.07; 0.20] [0.29; 0.59]	29.3% 12.4%	26.6% 23.9%
Fixed effect model Random effects model Heterogeneity: <i>I</i> <sup>2</sup> = 89%, τ <sup>2</sup>	= 0.0255	<b>372</b> 5, <i>p</i> < 0.0	0.3	0.4	0.5		[0.09; 0.16] [0.05; 0.30]		100.0%

Study	Events Total	al	Slee	p_diso	rders		Proportion	95%-CI	Weight (fixed)	Weight (random)
Sonnweber, et al.	38 14	5 —					0.26	[0.19; 0.34]	40.7%	40.7%
nedRxiv preprint doi: https://doi.org/10.101/2021.10.17.21265123; this version posted October 18, 2021. The copyright holder for this pro (which was not derivide by preprint in perpetuit is made available under a CC-8x4 C 4.0 International license.	28 9	1 -				355	0.31	[0.22; 0.41]	25.6%	25.6%
Garrigues, et al.	37 12	0	§ <del>-</del>			<del></del>	0.31	[0.23; 0.40]	33.7%	33.7%
Fixed effect model	35	6					0.29	[0.24; 0.34]	100.0%	
Random effects model		10019			_		0.29	[0.24; 0.34]		100.0%
Heterogeneity: $I^2 = 0\%$ , $\tau^2$	= 0, p = 0.64	36	<u> </u>							
		0.2	0.25	0.3	0.35	0.4				

Study	Events	Total	Sore	_throat	pain	P	roportion	95%-CI	Weight
edRxiv preprint doi: https://goi.olg/10.1191/2021-10.17-21265123, this version posted occuber 15, 2021. The copyright holder for this preprint	8	187 —	10000				0.04	[0.02; 0.08]	63.1%
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.	5	109 —		-			1,000,000,000	[0.02; 0.10]	
Random effects mode Heterogeneity: I <sup>2</sup> = 0%, τ		<b>296</b> 85					0.04	[0.02; 0.07]	100.0%
		0.0	2 0.04	0.06	0.08	0.1			

Study	Events	Total		Sputum		Proportion	95%-CI	Weight (fixed)	Weight (random)
Zhao, et al.	1	55 +				0.02	[0.00; 0.10]	19.4%	33.0%
medRxiv preprint doi: https://doi.org/10.1101/2021.10.17.21265.23; this version posted October 18, 2021. The copyright holder for this particle with the preprint in perpetual by peer review is nearly and the preprint in perpetual transfer available of der a CC-BY-NC 4.0 International license.	preprint 27	183				0.15	[0.10; 0.21]	64.3%	34.3%
Park, et al.	26	46	1 :			0.57	[0.41; 0.71]	16.3%	32.7%
Fixed effect model		284				0.17	[0.12; 0.21]	100.0%	
Random effects model							[0.01; 0.51]		100.0%
Heterogeneity: $I^2 = 96\%$ , $\tau^2$	= 0.0795	5, p < 0.0	1						
		C404-0404 TAP (5004) 6		0.3 0.4 0.5	5 0.6 0.	7			